A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)
Sponsor: Merck Sharp & Dohme Corp.
This PHASE3 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Merck Sharp & Dohme Corp. leads this study, which shows 12 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Nov 2019 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme Corp.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.